Connect with us
  • Elysium

Brain injury news

Study reveals evidence of first pharmacologic treatment for concussion



Researchers have found early evidence of the first potential pharmacologic treatment for concussion, which may aid in the recovery of teenagers and young adults following a mild traumatic brain injury.

Scientists from the Minds Matter Concussion Frontier Program at Children’s Hospital of Philadelphia (CHOP) have found preliminary evidence that adolescents and young adults with concussion, who took a specific formulation of branched chain amino acid (BCAA) supplements after injury, experienced faster symptom reduction and return to physical activity.

The findings from what is said to be the first clinical trial of a targeted pharmacologic therapeutic for mild traumatic brain injury in paediatric patients, were published online by the Journal of Neurotrauma.

More than two million concussions occur in the youth and adolescent population in the United States each year.

The main form of treatment remains symptom management with temporary modification of cognitive and physical activity and over the counter medication.

Although active rehabilitation strategies have shown promise for improving recovery time, including aerobic, vestibular, and vision interventions, these can be time and labor intensive. To date, no targeted pharmacologic intervention to improve clinical outcomes in concussion has been evaluated in humans.

Animal model studies of mild to moderate traumatic brain injury, which have been led by the study’s senior author, Akiva S Cohen, PhD, Professor of Neuroscience in the Department of Anesthesiology and Critical Care Medicine at CHOP and a research professor of Anesthesiology and Critical Care at the Perelman School of Medicine of the University of Pennsylvania, have shown that supplementation with a specific formulation of three BCAAs – leucine, isoleucine and valine – improve neurocognitive function.

However, prior to this study, no human studies involving adolescents and young adults have assessed the potential benefits of this formulation of BCAAs as a specific treatment to aid in concussion recovery.

“The goal of this pilot study was to determine, among several different doses, whether our specific formulation of BCAAs could accelerate recovery – faster reduction in symptoms and return to baseline physical activity,” Cohen said.

“Based on our work in animal models, we expected that our specific formulation of BCAA supplementation would result in a more rapid resolution in symptom burden and improved physical activity levels which are key measures of recovery from a concussion.”

The study in more detail

The scientists conducted a pilot, double-blind, randomised controlled trial of participants between the ages of 12-30 years who presented with concussion to outpatient clinics, urgent care and emergency departments across the CHOP Network between June of 2014 and December of 2020.

Individual participants were divided into five groups consisting of a placebo arm and different treatment arms of 15 g, 30 g, 45 g and 54 g doses of a specific formulation of BCAAs.

The participants were followed for a period of 21 days after enrolment and were assessed with daily computerised neurocognitive tests, reported symptom score, physical and cognitive activity, treatment compliance and adverse events. A total of 38 participants had analysable data at the end of the study.

Researchers found that there was a significant reduction in and faster resolution of the total symptom score in a dose-dependent fashion with the specific formulation of BCAA supplementation, with a significant decrease in total symptoms across the study.

Similar significant improvements were seen in a faster return to physical activity, with an increase of 0.5 on a 0-5 scale of physical activity for each 500 g of the defined BCAA supplement consumed.

The treatment was very well tolerated; no serious adverse events were reported in the study, and there were no differences in mild adverse events between the placebo and treatment groups.

The study’s first author Daniel Corwin, MD, MSCE, Assistant Professor of Pediatrics and Emergency Department Lead of the Minds Matter Concussion Frontier Program at CHOP, commented:  “Our results demonstrate that our specific formulation of BCAA supplementation is a highly promising treatment that addresses the underlying mechanism driving concussion symptoms in order to accelerate recovery and improve outcomes.

“While a larger study is needed to confirm the formulation’s efficacy before routine use of BCAA supplementation should be recommended, we are extremely encouraged by these preliminary findings, the first trial to demonstrate that a targeted pharmacologic using a specific formulation of BCAAs may be useful as a treatment for youth and young adult concussion.”